New Methods in Coagulation

References

• Davie E. W., Fujikawa K., Kurachi K., Kisiel W. Role of serine-proteases in the blood coagulation cascade. Ad. Enzymol, Relat, Areas Mol. Biol. 1979; 48: 277
   PubMedGoogle Scholar
• Baugh R. F., Hogie C. The chemistry of blood coagulation. Clin. Haemarol. 1979; 8(1)3
   PubMedGoogle Scholar
• Hauschka P. V., Lian J. B., Gallop P. M. Direct identification of the calcium binding amino acid, Y-carboxyglutamates in mineral tissue. Proc. Natl., Acad. Sci. USA. 1975; 72: 3925
   PubMed Web of Science ®Google Scholar
• Kisiel W., Canfield W. M., Ericeson L. H., Davie E. W. Anticoagulant properties of Bovine plasma protein C following activation by thrombin. Biochemistry 1977; 16: 5824
   PubMed Web of Science ®Google Scholar
• Jesty J., Maynard J. R., Raddiffe R. D., Silverberg S. A., Pitlock F. A., Nemerson Y. Initiation and control of the extrinsic pathway of blood coagulation. Proteases and Bioiogical Control, E. Reich. Cold Springs Harbor, New York 1975; 171
   Google Scholar
• Denson K. W. E. The Use of Antibodies in the Studies Blood Coagulation. Blackwell Scientific, Oxford 1967
   Google Scholar
• Laurell C. B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal. Biochem. 1966; 15: 45
   PubMed Web of Science ®Google Scholar
• Giddings J. C., Evans D. J., Bloom A. L. Quantitation of factor VIII related antigen (FVIIIRAG) using laser nephelometer. Thromb. Res. 1979; 15: 847
   Google Scholar
• Clarke H. G. M., Freeman T. Quantitative immunoelectrophoresis of human serum proteins. Clin. Sci. 1968; 35: 403
   PubMed Web of Science ®Google Scholar
• Holmberg L., Borge L., Ljung R., Nilsson I. M. Measurement of antihemophilic factor A antigen (VII:CAg) with a solid phase immunoradiometnc method based on homologous non-haernophilic antibodies. Scand. J. Haematol. 1979; 23: 17
   Google Scholar
• Lazarchick J., Hoyer L. A. Immunoradiometric measurement of factor VIII procoagulant antigen. J. Clin. Invest. 1978; 62: 1048
   Google Scholar
• Bartlett A., Dormandy K. M., Hawkey C. M., Stableforth P., Voller A. Factor VIII-related antigen: measurement by enzyme immunoassay. Br. Med. J. 1976; 1: 994
   Google Scholar
• Yorde L. D., Hussey C. V., Yorde D. E., Sasse E. A. Competitive enzyme linked immunoassay for factor VIII antigen. Clin. Chem. 1979; 25: 1924
   Google Scholar
• Ness P. M., Perkins H. A. A simple enzyme-immunoassay (EIA) test for factor VIII-related antigen (VIII AGN). Thromb. Haemost. (Stutrgart) 1979; 42: 848
   Google Scholar
• Imperato D. C., Dettori A. G. Ipofibrinogenemia congenita con fibrinoastenia. Helv. Paediatr. Acta 1958; 13: 380
   Google Scholar
• Morse E. E. The fibrinogenopathies. Ann. Clin. Lab. Sci. 1978; 8(3)234
   Google Scholar
• Mammen E. F., Prasad A. S., Barnhard M. I., Au C. C. Congenial dysfibrinogenemia molecular abnormalities of finbrinogen. Blut 1976; 33: 229
   Google Scholar
• Marder V. J. The functional defects of hereditary dysfibrinogens. Thromb. Haemost. (Stuttgart) 1976; 36: 1
   Google Scholar
• Martinez J., Holburn R. R., Shapiro S. S., Ersley A. J. Fibrinogen Philadelphia, a hereditary hypodysfibrinogenemia characterized by fibrinogen hypercatabolism. J. Clin. Invest. 1974; 53: 600
   Google Scholar
• Owen C. A., Bowei E. F. W., Fass D. N., Perez R. A., Cole T. L., Stewart M. Hypofibrinogenemiadysfibrinogenemia and von Willebrand's disease in the same family. Mayo Clin. Proc. 1979; 54: 375
   Google Scholar
• Gralnick H. R., Collar B. S., Frantantoni J. C., Martinez J. Fibrinogen Bethesda III: a hypodysfibrinogenemia. Blood 1979; 53(1)28
   Google Scholar
• von Felton A., Straub P. W., Frick P. G. Dysfibrinogenemia in a patient with primary hepatoma; first observation of an acquired abnormality of fibrin monomer aggregation. N. Engl. J. Med. 1969; 280(8)405
   Google Scholar
• Barn R. D., Ouna N., Simpson J. G., Bagshawe A. F. Dysfibrinogenemia and primary hepatocellular carcinoma. Q. J. Med., Ser. 1976; XLV(180)647
   Google Scholar
• Palascak J. E., Martinez J. Dysfibrinogenemia associated with liver disease. J. Clin. Invest. 1977; 60: 89
   PubMed Web of Science ®Google Scholar
• Lane D. A., Scully M. F., Thomas D. P., Kakkar V. V., Woolf I. L., Williams R. Acquired dysfibrinogenemia in acute and chronic liver disease. Br. J. Haematol. 1977; 35: 301
   Google Scholar
• Barr R. D., Allardyce M., Brunt P. W., McPhie J. L. Dysfibrinogenaemia and liver cell growth. J. Clin. Pathol. 1978; 31: 89
   Google Scholar
• Grainick H. R., Givelber H., Abrams E. Dysfibrinogenemia associated with hepatoma. N. Engl. J. Med. 1978; 299(5)221
   Google Scholar
• Martinez J., Palascak J. E., Kwasniak D. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. J. Clin. Invest. 1978; 61: 535
   Google Scholar
• Shapiro S., Martinez J., Holburn R. R. Congenital dysprothrombinemia: an inherited structural disorder of human prothrombin. J. Clin. Invest. 1969; 48: 2251
   PubMed Web of Science ®Google Scholar
• Josso F., Monasterio de Sanchez J., Lavugne J. M., Menache D., Soulier J. P. Congenital abnormalities of the prothrombin molecule (factor II) in four siblings: Prothrombin Barcelona. Blood. 1971; 38: 9
   PubMed Web of Science ®Google Scholar
• Rabiet M. J., Benarous R., Labie D., Josso F. Abnormal activation of a human prothrombin variant: prothrombin Barcelona. FEBS Lerrers 1978; 87(1)132
   Google Scholar
• Rabiet M. J., Elion J., Benarous R., Labie D., Josso F. Activation of prothrombin Barcelona evidence for active high molecular weight intermediates. Biochim. Biophys. Acta 1979; 584: 66
   Google Scholar
• Girolami A., Bareggi G., Brunetti A., Sticchi A. Prothrombin Padua: a “new” congenital dysprothrombinemia. J. Lab. Clin. Med. 1974; 84: 654
   Google Scholar
• Girolami A., Giovanni P., Virgolini L., et al. The effect of several vipor venoms on prothrombin Padua. Blut 1975; 31: 155
   Google Scholar
• Kahn M. J. P., Govaerts A. Prothrombin Brussels, a new congenital defective protein. Thromb. Res. 1974; 5: 141
   Google Scholar
• Shapiro S. S. Prothrombin San Juan: a new complex dysprothrombinemia. Prothrombin and Related Factors, H. C. Hemker, J. J Veltkamp. Leiden University Press, Netherlands 1975
   Google Scholar
• Shapiro S. S., Maldonado N. I., Fradera J., McCord S. Prothrombin San Juan: a complex new dysprothrombinemia. J. Clin. Invest. 1974; 53: 73A
   Google Scholar
• Bezeaud A., Guillin C., Olmeda F., Quintana M., Gomez N. Prothrombin Madrid: a new familial abnormality of prothrombin. Thromb. Res. 1979; 16: 47
   Google Scholar
• Girolami A., Coccheri S., Palareti G., Poggi M., Burul A., Capellato G. Prothrombin Molise: a “new” congenital dysprothrombinemia double heterozygous with an abnormal prothrombin and true prothrombin deficiency. Blood. 1978; 52: 115
   Google Scholar
• Josso F., Rio Y., Begun S. Prothrombin Metz: a new variant of human prothrombin. Double heterozygousity for congenital hypothrombinemia and dysprothrombinemia. 17th Cong. Int. Soc. Hematol.; 15th Cong. Int. Soc. Blood Trans. Paris 1978; 860, Abstr.
   Google Scholar
• Owen C. A., Henriksen R. A., McDuffie F. C., Mann K. G. Prothrombin Quick, a newly identified dysprothrombinemia. Mayo Clin. Proc. 1978; 53: 29
   Google Scholar
• Poon M. C., Moore M., Prchal J. T., Weir A. B. Prothrombin Birmingham (PB): a new structurally abnormal prothrombin. Blood 1979; 297a, (Suppl.), 822 (Abstr.)
   Google Scholar
• Weinger R. S., Rudy C., Moake J. L., Olson J. D., Conklin G., Cimo P. L. Dysprothrombinemia: prothrombin Houston. Blood 1979; 197, (Suppl.), 369 (Abstr.)
   Google Scholar
• Weinger R. S., Rudy C., Moake J. L., Olson J. D., Cimo P. L. Prothrombin Houston: a dysprothrombin identifiable by crossed immunoelectrofocusing and abnormal Echis Carinatus venom activation. Blood 1980; 55: 811
   Google Scholar
• Prydz H. H., Gladhaug A. Factor X immunological studies. Thromp. Diath. Haemorrh. 1971; 25: 157
   Google Scholar
• Denson K. W. E., Lurie A., DeCataldo F., Mannucci P. M. The factor-X defect: recognition of abnormal forms of factor X. Br. J. Haematol. 1970; 18: 317
   PubMed Web of Science ®Google Scholar
• Girolami A., Molaro G., Lazzarin M., Carpa R., Burnetti A. Congenital hemorrhagic conditions similar but not identical to factor X deficiency. A hemorrhagic state due to abnormal factor X?. Scand. J. Haemaiol. 1970; 7: 91
   Google Scholar
• Girolami A., Molaro G., Lazzarin M., et al. A “new” congenital hemorrhagic condition due to the presence of an abnormal factor X (factor X Friuli): study of a large kindred. Br. J. Haematol. 1970; 19: 177
   Google Scholar
• Girolami A., Lazzarin M., Scarpa R., et al. Further studies on the abnormal factor X (factor X Friuli). Blood 1971; 37: 534
   PubMed Web of Science ®Google Scholar
• Girolami A., Stuchi A., Bareggi G. Crossover electrophoresis (electrosyneresis) visualization of the abnormal factor X (factor X Friuli). J. Lab. Clin. Med. 1972; 80: 740
   Google Scholar
• Girolami A., Bareggi G., Fioretti D. Different cross-over electrophoresis (electrosyneresis) mobility of factor X Friuli and coumann induced abnormal factor X. Haemosrmis 1972–1973; 1: 229
   Google Scholar
• Girolami A., Nicoletti R., Furlani P., Bareggi G. Abnormal factor X (factor X Friuli) coagulation disorder. First report of a case outside Friuli. Acta Haemotol. 1973; 49: 114
   Google Scholar
• Girolami A., Brunetti A., Bareggi G., et al. Abnormal factor X (factor X Friuli) coagulation disorder. The herterozygote population. Acta Haematol. 1974; 51: 40
   Google Scholar
• Girolami A., Falomo R., DeMnrco L., Patrassi G. Factor X Friuli coagulation disorder. Acta Haematol. 1976; 56: 27
   Google Scholar
• Girolami A., Saggin L., Boeri G. Factor X assays using chromogenic substrate S-2222. Am. J. Clin. Pathol. 1980; 73: 402
   Google Scholar
• Fair D. S., Plow E. F., Edgington F. S. Combined functional and immunochemical analysis of normal and abnormal human factor X. J. Clin Invest. 1979; 64: 884
   Google Scholar
• Goodnight S. H., Feinstein D. I., Osterud B., Rapaport S. I. Factor VII antibody-neutralizing material in hereditary and acquired factor VII deficiency. Blood 1971; 38: I
   Google Scholar
• Denson K. W. E., Conard J., Samama M. Genetic variants of factor VII. Lancet June 3, 1972; 1234
   Google Scholar
• Briet E., Loeliger E. A., Tilburg N. H., Veltkamp J. J. Molecular variant of factor VII. Thromb. Hemost. (Stuttgart). 1976; 35: 289
   Google Scholar
• Levanon M., Rimon S., Shari M., Ramot S., Goldberg E. Active and inactive factor VII in Dubin Johnson syndrome with factor VII deficiency and on coumadin administration. Br. J. Haemalol. 1972; 23: 669
   Google Scholar
• Kroll A. J., Alexander B., Cochios F., Pechet L. Hereditary deficiencies of clotting factors VII and X associated with carotid-body tumors. N. Engl. J. Med. 1964; 270: 6
   Google Scholar
• Mazzucconi M. G., Mandelli F., Mariani G., Briet E., Veltkamp J. J. A CRM-positive variant of factor VII deficiency and the detection of heterozygotes with the assay of factor-like antigen. Br. J. Haematol. 1977; 36: 127
   Google Scholar
• Girolami A., Fabris F., Dal Bo Zanon R., Chiotto G., Burull A. Factor VII Padua: a congenital coagulation disorder due to an abnormal factor VII with a peculiar activation pattern. J. Lab. Clin. Med. 1978; 91(3)387
   Google Scholar
• Girolami A., Patrssi G., Cappellato G., Casonato A. Another family with the factor VII Padua clotting defect. Acta Haematol. 1979; 62: 4
   Web of Science ®Google Scholar
• Girolami A., Cattarozzi G., Dal Bo Zanon R., Cella G., Toffanin F. Factor VII Padua 2: another factor VII abnormality with defective ox brain thromboplastin activation and a complex hereditary pattern. Blood 1979; 54(1)46
   Google Scholar
• Girolami A., Falezza G., Patrassi G., Stenico M., Vettore L. Factor VII Verona coagulation disorder: double heterozygosis with an abnormal factor VII nd heterozygous factor VII deficiency. Blood 1977; 50: 603
   PubMed Web of Science ®Google Scholar
• Mazzucconi M. G., Orlando M., Hassan H. J., Romoli D., Mariani G. Factor VII activity and cross reacting material in normal individuals. Thromb. Res. 1979; 14: 241
   Google Scholar
• Richards M. D., Spaet T. H. Immunization of rabbits against human antihemophilic factor. Blood 1956; 11: 473
   Google Scholar
• Shanberge J. N., Gore I. Studies on the immunologic and physiologic activities of antihemophilic factor (AHF). J. Lab. Clin. Med. 1957; 50: 954, (Abstr.)
   Web of Science ®Google Scholar
• Hoyer L. W., Breckenridge R. T. Immunologic studies of anti-hemophilic factor (AHF factor VIII): cross reacting material in a genetic variant of hemophilia A. Blood 1968; 32: 962
   PubMed Web of Science ®Google Scholar
• Denson K. W. E., Biggs R., Haddon M. E., Borrett R., Cobb K. Two types of haemophilia (A+ and A-): a study of 48 cases. Br. J. Haematol. 1969; 17: 163
   PubMed Web of Science ®Google Scholar
• Zimmerman T. S., Ratnoff O. D., Powell A. E. Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand-s disease. J. Clin. Invest. 1971; 50: 244
   PubMed Web of Science ®Google Scholar
• Howard M. A., Firkin B. C. Ristocetin: a new tool in the investigation of platelet aggregation. Thromb. Diath. Haemorrh. 1971; 26: 362
   PubMedGoogle Scholar
• Howard M. A., Firkin B. G. Factor VIII physiology and pathology in man. Prog. in Hemarol. 1979; 11: 115
   Google Scholar
• Green D. Hemophilia and von Willebrand's disease: genetic considerations. Ann. Clin. Lab. Sci. 1980; 10(2)123
   Google Scholar
• Bloom A. L. Factor VIII: new clinical and genetic aspects. Schweiz. Med. Wochenschr. 1979; 109: 1357
   Google Scholar
• Nilsson L. M. Report of the working party on factor VIII-related antigens. Thromb. Haemost., (Stutigart) 1978; 39: 511
   Google Scholar
• Ruggeri Z. M., Mannucci P. M., Jeffcoate S. L., Ingram G. I. C. Immunoradiometric assay of factor VIII related antigen, with observations in 32 patients with von Willebrand's disease. Br. J. Haemarol. 1976; 33: 221
   PubMed Web of Science ®Google Scholar
• Rudzki Z., Tunbridge L. J., Lloyd J. V. A new simple assay for factor VIII related antigen. Thromb. Res. 1979; 16: 577
   Google Scholar
• Ramsey R., Evatt B. L. Rapid assay for von Willebrand factor activity using formalin-fixed platelets and microtitration technic. Am. J. Clin. Pathot. 1979; 72(6)996
   Google Scholar
• Head D. R., Bowman R. P., Marmer D. J., Brossoit A. D. An improved assay for von Willebrand factor. Am. J. Clin. Pathol. 1979; 72(6)991
   Google Scholar
• Veltkamp J. J., Van Tilburg N. H. Autosomal haemophilia and a variant of von Willebrand's disease. Br. J. Haematot. 1974; 26: 141
   Google Scholar
• Kernoff P. B. A., Gruson R., Rizza C. R. A variant of factor VIII related antigen. Br. J. Haemarol. 1974; 26: 435
   Google Scholar
• Thomson C., Forbes C. D., Prentice C. R. M. Evidence for a qualitative defect in factor-VIII related antigen in von Willebrand's disease. Lancet April 6, 1974; 594
   Google Scholar
• Peake I. R., Bloom A. L., Giddings J. C. Inherited variants of factor-VIII-related protein in von Willebrand's disease. N. Engl. J. Med. 1974; 291(3)113
   Google Scholar
• Gralnick H. R., Coller B. S., Sultan Y. Studies of the human factor VIII/von Willebrand factor proten. J. Clin. Invest. 1975; 56: 814
   Google Scholar
• Hill F. G. H., Chan M. C. K., Hardisty R. M. Von Willebrand's syndrome studies of a varient factor VIII. Hoemostasis. 1976; 5: 276
   Google Scholar
• Sultan Y., Simeon J., Caen J. P. Electrophoretic heterogeneity of normal factor VIII/von Willebrand proten, and abnormal electrophoretic mobility in patients with von Willebrand's disease. J. Lab. Clin. Med. 1976; 87: 185
   Google Scholar
• Gralnick H. R., Colter B. S., Sultan Y. Carbohydrate deficiency of the factor VIII/von Willebrand factor protein in von Willebrand's disease variants. Science 1976; 192: 56
   Google Scholar
• Ananthakrishnan R., D'Souza S., Ekert H. Studies on the altered electrophoretic type of the factor VIII related antigen. Hum. Genet. 1976; 35: 71
   Google Scholar
• Gralnick H. R., Sultan Y., Coller B. S. von Willebrand's disease, combined qualitative and quantitative abnormalities. N. Engl J. Med. 1977; 296(18)1024
   Google Scholar
• Rivard G. E., Daviault M. B., Brault N., D'Aragon L., Raymond R. von Willebrandt's disease associated with thrombocytopenia and a fast migrating factor VIII related antigen. Thromb. Res. 1977; 11: 507
   Google Scholar
• Ardaillou N., Girma J. P., Meyer D., Lavergne J. M., Shoa'i J., Larrieu M. J. “Variants” of von Willebrand's disease. Demonstration of a decreased antigenic reactivity by immunoradiometric assay. Thromb. Res. 1978; 12(5)817
   Google Scholar
• Montgomery R. R., Zimmerman T. S. Von Willebrand's disease antigen II: a new plasma and platelet antigen deficient in severe von Willebrand's disease. J. Clin. Invest. 1978; 61: 1498
   Google Scholar
• Armitage H., Rizza C. R. Two populations of factor VIII-related antigen in a family with von Willebrand's disease. Br. J. Haematol 1979; 41: 279
   Google Scholar
• Zimmerman T. S., Abildgaard C. F., Meyer D. The factor VIII abnormality in severe von Willebrand's disease. N. Engl. J. Med. 1979; 301(24)1307
   Google Scholar
• Green D., Philip K. J. Variant von Willebrand's disease a study emphasizing crossed immunoelectrophoresis. Thromb. Haemost. (Stuttgart) 1980; 43: 2
   Google Scholar
• Howard M. A., Hendrix L., Firkin B. G. Further studies on the factor VIII of a patient with a variant form of von Willebrand's disease. Thromb. Res. 1979; 14: 609
   Google Scholar
• Zimmerman T. S., Ratnoff O. D., Littell A. S. Detection of carriers of classic hemophilia using an immunologic assay for antihemophilic factor (factor VIII). J. Clin. Invest. 1971; 50: 255
   PubMed Web of Science ®Google Scholar
• Graham J. B., Barrow E. S., Elston R. C. Carrier detection in hemophilia. Am. J. Hum. Genet. 1973; 25: 30a
   Google Scholar
• Bowie E. J., Fass D. N. Factor VIII related antigen (VIII R:Ag) in haemophilic patients and in carriers. Lancet 1979; ii: 1049
   Google Scholar
• Girolami A., Sticchi A., Cappelato G., Quaino V. Factor VIII antigen prepeak. Lancet 1980; i: 263, (Letter)
   Google Scholar
• Fantl P., Sawers R. J., Marr A. G. Investigation of a haemorrhagic disease due to betathromboplastin deficiency complicated by a specific inhibitor of thromboplastin formation. Auslralas. Ann. Med. 1956; 5: 163
   PubMedGoogle Scholar
• Kidd P., Denson K. W. E., Biggs R. The thrombotest reagent and Christmas disease. Lancet 1963; 2: 522
   PubMedGoogle Scholar
• Hougie C., Twomey J. J. Haemophila Bm a new type of factor IX deficiency. Lancet 1967; i: 698
   Google Scholar
• Twomey J. J., Confess J., Thornton L., Hougie C. Studies on the inheritance and nature of haemophilia Bm. Am. J. Med. 1969; 46: 372
   Google Scholar
• Roberts H. R., Grizzel J. E., McLester W. D., Penick G. D. Genetic variants of hemophilia B: detection by means of specific PTG inhibitor. J. Clin. Invest. 1968; 47: 360
   Google Scholar
• Bertina R. M., van der Linden I. K. Inhibitor, neutralization assay and electroimmunoassay of human factor IX (Christmas factor). Clin. Chim. Acta 1977; 77: 275
   Google Scholar
• Orstavik K. H. Comparison of precipitating antisera against normal and abnormal factor IX. Thromb. Res. 1977; 10: 731
   Google Scholar
• Thompson A. R. Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with haemophilia B. J. Clin. Invest. 1977; 59: 900
   Google Scholar
• Thompson A. R. Factor IX antigen by radioimmunoassay in heterozygotes for haemophilia B. Thromb. Res. 1977; 11: 193
   Google Scholar
• Yang H. C. Immunologic studies of factor IX (Christmas factor): I. Counterimmunoelectrophoresis method for factor IX antigen. Thromb. Res. 1978; 13: 97
   Google Scholar
• Lewis R. M., Reisner H. M., Chung K. S., Roberts H. R. Radioimmunoassay for antibodies to human factor IX. Fed. Proc. Fed. Am. Soc. Exp. Biol. 1979; 38: 1410
   Google Scholar
• Yang H. C., Haddow J. E. Comparative factor IX antigen measurement by goat and rabbit anti-sera (meeting abstr). Clin. Res. 1979; 27: A310
   Google Scholar
• Denson K. W. E., Biggs R., Mannucci P. M. An investigation of three patients with Christmas disease due to an abnormal type of Factor IX. J. Clin. Pathol. 1968; 21: 160
   PubMed Web of Science ®Google Scholar
• Pfueller S., Somer J. B., Castaldi P. A. Haemophilia B due to an abnormal factor IX. Coagulation 1969; 2: 213
   Google Scholar
• Bithell T. C., Pizarro A., MacDiarmid W. D. Variant of factor IX deficiency in female with 45-X Turner's syndrome. Blood 1970; 36: 169
   Google Scholar
• Brown P. E., Hougie C., Roberts H. R. The genetic heterogeneity of haemophilia B. N. Engl. J. Med. 1970; 283: 61
   Google Scholar
• Meyer D., Bidwell E., Larrieu M. J. Cross reacting material in genetic variants of haemophilia B. J. Clin. Pathol. 1972; 25: 433
   Google Scholar
• Mazzuconi M. G., Bertina R. M., Romoli D., Orlando M., Avrisati G., Marian G. Factor VIII activity and antigen in haemophilia B variants. Thromb. Haemost. (Stuttgart) 1980; 43: 16
   Google Scholar
• Elodi S., Puskas E. Variants of haemophilia B. Thromb. Diath. Haemorrh. 1972; 28: 489
   Google Scholar
• Denson K. W. E. Editorial: molecular variants of haemophilia B. Thromb. Diath. Haemorrh. 1973; 29: 217
   Google Scholar
• Girolami A., Sticchi A., Burul A., Zanon R. D. An immunologic investigation of haemophilia B with a tentative classification of the disease into five variants. Vox Sang. 1977; 32: 230
   Google Scholar
• Roberts H. R., Chung K. S., Goldsmith J. C. Genetic variants of haemophilia B. Thromb. Haemost. (Stuttgart) 1977; 38: 116
   Google Scholar
• Parekh V. R., Mannucci P. M., Ruggeri Z. M. Immunological heterogeneity of haemophilia B: a multicentre study of 98 kindreds. Br. J. Haematol. 1978; 40: 643
   Google Scholar
• Bertina R. M., Veltkamp J. J. The abnormal factor IX of hemophilia B* variants. Thromb. Haemost. (Stuttgart) 1978; 40: 335
   Google Scholar
• Bertina R. M., Veltkamp J. J. A genetic variant of factor IX with decreased capacity for Ca2* binding. Br. J. Haematol. 1979; 42: 623
   Google Scholar
• Osterud B., Kasper C. K., Prodanos C. Factor IX variants of hemophilia B. The effect of activated factor XI and the reaction product of factor VII and tissue factor on the abnormal factor IX molecules. Thromb. Res. 1979; 15: 235
   Google Scholar
• Osterud B., Lavine K., Kasper D. K., Rapaport S. I. Isolation and properties of the abnormal factor IX molecule or haemophilia Bm. Thromb. Haemost. (Stuttgart) 1977; 38: 51
   Google Scholar
• Girolami A., Cella G. Hemophilia Bm: first case report in Italy. Blut 1973; 26: 268
   Google Scholar
• Kasper C. K., Osterud B., Minami J. Y., Shonick W., Rapaport S. I. Hemophilia B: characterization of genetic variants and detection of carriers. Blood 1977; 50: 351
   Google Scholar
• Chung K. S., Madar D. A., Goldsmith J. C., Kingdon H. S., Roberts H. R. Purification and characterization of an abnormal factor IX (Christmas factor) molecule, factor IX Chapel Hill. J. Clin. Invest. 1978; 62: 1078
   Google Scholar
• Veltkamp J. J., Meilof J., Remmelts H. G., van der Vlerk D., Loeliger E. A. Another genetic variant of haemophilia B Leyden. Scand. J. Haematol. 1970; 7: 82
   Google Scholar
• Matsuoka M., Ito M., Takahashi K., Shauragawa N. An immunologic method for detection of the carrier of haemophilia B. Thromb. Haemost. (Stuttgart) 1976; 36: 441
   Google Scholar
• Pechet L., Tiarks C. Y., Stevens J., Sudhindra R. R., Lipworth L. Relationship of factor IX antigen and coagulant in hemophilia B patients and carriers. Thromb. Haemost. (Stuttgart) 1978; 40: 465
   Google Scholar
• Ostavik K. H., Veltkamp J. J., Bertina R. M., Hermans J. Detection of carriers of haemophilia B. Br. J. Haematol. 1979; 42: 293
   Google Scholar
• Lipworth L., Tiarks C. Y., Rice C. A., Pechet L. Laboratory prediction of the carrier state in hemophilia B; role of replication of assays. Am. J. Clin. Pathol. 1979; 72: 1000
   Google Scholar
• Orstavik K. H., Vennrod A. M., Laake K. Studies of human factor IX by high titred sheep antiserum against factor IX. Thromb. Res. 1979; 11: 653
   Google Scholar
• Suomela H. Multiple forms of human factor IX in chromatography and isoelectric focusing. Thromb. Res. 1975; 7: 101
   Google Scholar
• McMillan C. W., Roberts H. R. Congenital combined deficiency of coagulation factors II, VII, IX and X. N. Engl. J. Med. 1966; 274: 1313
   PubMedGoogle Scholar
• Chung K. S., Bezeaud A., Goldsmith J. C., McMillan C. W., Menache D., Roberts H. R. Congenital deficiency of blood clotting factors II, VII, IX and X. Blood 1979; 53: 776
   Google Scholar
• Johnson C. A., Chung K. S., McGrath K. M., Bean P. E., Roberts H. R. Characterization of a variant prothrombin in a patient congenitally deficient in factor II, VII, IX, X. Br. J. Haematol. 1980; 44: 461
   Google Scholar
• Smit Sibinga C. T. S., Gokemeyer J. D. M., ten Kate L. P., van Zwol Bos F. Combined deficiency of factor V and factor VIII: report of a family and genetic analysis. Br. J. Haematol. 1972; 23: 467
   Google Scholar
• Rimon A., Schiffman S., Feinstein D. I., Rapaport S. I. Factor XI activity and factor XI antigen in homozygous and heterozygous factor XI deficiency. Blood 1976; 48: 165
   Google Scholar
• Saito H., Golddsmith G. H. Plasma thromboplastin antecedent (PTA, factor XI): a specific and sensitive radioimmunoassay. Blood 1977; 50: 377
   Google Scholar
• Saito H., Scott J. G., Movat H., Scialla S. J. Molecular heterogeneity of Hageman trait (factor XII deficiency). J. Lab. Clin. Med. 1979; 94: 256
   Google Scholar
• Saito H., Scialla S. J. Isolation and properties of non-functional Hageman factor (HF, factor XII) from a CRM positive Hageman trait plasma. Blood 1979; 201, (Suppl.) 834 (Abstr.)
   Google Scholar
• Saito H., Scott J. G., Movat H. Z., Scialla S. J. CRM* variants of Hageman trait. Blood 1979; 8194, (Suppl.) 360 (Abstr.)
   Google Scholar
• Saito H., Ratnoff O. D. Molecular heterogeneity of human plasma prekallikrein deficiency (Fletcher trait). Clin. Res. 1977; 25: 347A, (Abstr.)
   Google Scholar
• Kane W. H., Lindout M. J., Jackson C. M., Majerus P. W. Factor Va-dependent binding of factor Xa to platelets. J. Biol. Chem. 1980; 255: 1170
   PubMed Web of Science ®Google Scholar
• Losowski M. S., Miloszewski K. J. A. Annotation, factor XIII. Br. J. Haematol. 1977; 37: 1
   Google Scholar
• McDonagh J., McDonagh R. P., Jr., Duckert F. Genetic aspects of factor XIII deficiency. Ann. Hum. Genet. (London) 1971; 35: 197
   Google Scholar
• Francis J. L., Todd P. J. Factor XIII deficiency, a family study by measurement of factor XIII subunits A and S. Acta Haematol. 1979; 62: 167
   Google Scholar
• Girolami A., Burul A., Sticchi A. Congenital deficiency of factor XIII with normal subunit S and lack of subunit A., report of a new family. Acta Haematol. 1977; 58: 17
   Google Scholar
• Girolami A., Burul A., Fabris F., Cappellato G., Betterle C. Studies on factor XIII antigen in congenital factor XIII deficiency. A tentative classification of the disease in two groups. Folia Haematol. (Leipzig) 1978; 105: 131
   Google Scholar
• Hemker H. C., Veltkamp J. J., Loeliger E. A. Kinetic aspects of the interaction of blood clotting enzymes. III. Demonstration of an inhibitor of prothrombin conversion in vitamin K deficiency. Thromb. Haemost. (Stuttgart) 1968; 19: 346
   Google Scholar
• Hemker H. C., Muller A. D., Loeliger E. A. Two types of prothrombin in vitamin K deficiency. Thromb. Haemost. (Stuttgart) 1970; 23: 633
   Google Scholar
• Larrieu M. J., Meyer D. Abnormal factor IX during anticoagulant treatment. Lancet 1970; ii: 1085
   Google Scholar
• Lechner K. Immune reactive factor IX in acquired factor IX deficiency. Thromb. Diath. Haemorrh. 1972; 27: 19
   Google Scholar
• Kasper C. K., Hoag M. S., Aggeler P. M., Stone S. Blood clotting factors in pregnancy: factor VIII concentration in normal and AHF deficient woman. Obstet. Gynecol. 1964; 24: 242
   Google Scholar
• Strauss H. S., Diamond L. K. Elevation of factor VIII (antihemophilic factor) during pregnancy in normal persons and in a patient with von Willebrand's disease. N. Engl. J. Med. 1963; 269: 1251
   Google Scholar
• Ingram G. I. C. Increase in antihaemophilic globulin activity following infusion of adrenaline. J. Physiol. (London) 1961; 156: 217
   Google Scholar
• Rizza C. R. Effect of exercise on the level of antihaemophilic globulin in human blood. J. Physiol. (London). 1961; 156: 128
   Google Scholar
• Bennett B., Ratnoff O. D. Changes in antihemophilic factor (AHF, factor VIII) procoagulant activity and AHF antigen in normal pregnancy and following exercise and pneumoencephalography. J. Lab. Clin. Med. 1972; 80: 256
   PubMedGoogle Scholar
• Mannucci P. M., Ruggeri A. M., Gagnatelli G. Nervous regulation of factor VIII levels in man. Br. J. Haematol. 1971; 20: 195
   Google Scholar
• Canale V. C., Hilgartner M. W., Smith C. H., et al. Effect of corticosteroids on factor VIII level. J. Pediatr. 1967; 71: 878
   Google Scholar
• Schiffman S., Rapaport S. I. Increased factor VIII levels in suspected carriers of hemophilia A taking contraceptives by mouth. N. Engl. J. Med. 1966; 275: 599
   Google Scholar
• Crowell E. B., Clatanoff D. U., Kiekhofer W. The effect of oral contraceptives on factor VIII levels. J. Lab. Clin. Med. 1971; 77: 551
   Google Scholar
• Egeberg O., Owren P. A. Oral contraception and blood coagulability. Br. Med. J? 1963; 1: 220
   PubMedGoogle Scholar
• Denson K. W. E. The ratio of factor VIII-related antigen and factor VIII biological activity as an index of hypercoagulability and intravascular clotting. Thromb. Res. 1977; 10: 107
   PubMedGoogle Scholar
• Lian E. C.-Y., Nunez R. L., Harkness D. R. In vivo and in vitro effects of thrombin and plasman on human factor VIII (AHF). Am. J. HematoL 1976; 1: 481
   Google Scholar
• Henriksson P., Holmberg L. Factor VIII activity and antigen in sick newborns with pathological proteolysis in blood. Acta Paedialr. Scand. 1978; 67: 83
   Google Scholar
• Thornton C. A., Bonnar J. Factor VIII-related antigen and factor VIII coagulant activity in normal and pre-eclamptic pregnancy. Br. J. Obstet. Gyn. 1977; 84: 919
   PubMedGoogle Scholar
• Redman C. W. G., Denson K. W. E., Beilin L. G., Bolton F. G., Stirrat G. M. Factor VIII consumation in pre-eclampsia. Lancet Dec. 17, 1977
   Google Scholar
• Bennett B., Oxnard S. C., Douglas A. S., Ratnoff O. D. Studies on antihemophilic factor (AHF, factor VIII) during labor in normal women, in patients with premature separation of the placenta, and in a patient with von Willebrand's disease. J. Lab. Clin. Med. 1974; 84: 851
   Google Scholar
• Ruggeri Z. M., Ponticelli C., Mannucci P. M. Factor VIII and chronic renal failure: is von Willebrand's factor implicated?. Br. Med. J. 1977; 2: 359
   Google Scholar
• Ruggeri Z. M., Ponticelli C., Mannucci P. M. Factor VIII and chronic renal failure. Br. Med. J. 1977; 1: 1085
   Google Scholar
• Howard M. A., Whitwort J. A., Hendrix L. E., Thomas K. B., Firkin B. J. Abnormal factor VIII in chronic renal failure. Med. J. Aust. 1979; I: 148
   Google Scholar
• Warrell R. P., Hultin M. B., Coller B. S. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure. Am. J. Med. 1979; 66: 226
   PubMed Web of Science ®Google Scholar
• Maisonneuve P., Sultan V. Modification of factor VIII complex properties in patients with liver disease. J. Clin. Pathol 1977; 30: 221
   PubMedGoogle Scholar
• Sultan Y., Maisonneuve P., Simeon J., Inrrator L. Modifications of factor VIII related antigen in hemophiliacs with acute hepatitis and sub-clinical liver disease. Scand. J. Haematol. 1976; 16, (Suppl.)
   Google Scholar
• Lufkin E. G., Fass D. N., O'Fallon W. M., Bowie E. J. W. Increased von Willebrand factor in diabetes mellitus. Metabolism 1979; 28(1)63
   Google Scholar
• Barber A. G., Kaser-Glanzmann R., Jakabova M., Luscher E. F. Characterization of chon-droitin sulfate proteoglycan carrier for heparin neutralizing activity (PF4) released from human blood platelets. Biochim. Biophys. Acta 1972; 286: 316
   Google Scholar
• Moore S., Pepper D. S., Cash J. D. Platelet antiheparin activity: the isolation and characterization of platelet factor 4 released from thrombin aggregated washed human platelets and its dissociation into subunits and the isolation of membrane bound antiheparin activity. Biochim. Biophys. Acta. 1975; 379: 370
   Google Scholar
• Walz D. A., Wu V. Y., Delamo R., McCoy L. E. Primary structure of human platelet factor 4. Thromb. Res. 1977; 11: 833
   Google Scholar
• Niewiarowski S., Levine S. P. Characterization and assay of platelet secretory proteins. CRC Handbook Series, in Clinical Laboratory Sciences, Sect. I, R. M. Schmidt. CRC Press, Boca Raton, Florida 1979; Vol. 1: 435
   Google Scholar
• Niewiarowski S., Walz D. A., James P., Rucinski B., Kueppers F. Identification and separation of secreted platelet proteins by isoelectric focusing. Evidence that low-affinity platelet factor 4 is converted to β-thromboglobulin by limited proteolysis. Blood. 1980; 55(3)453
   Google Scholar
• Moore S., Pepper D. S., Cash J. D. The isolation and characterization of a platelet-specific β-globulin (β-thromboglobulin) and the detection of antiurokinase and antiplasmin released from thrombin-aggregated washed human platelets. Biochim. Biophys. Acta 1975; 379: 360
   Google Scholar
• Ludlam C. A., Moore S., Bolton A. E., Pepper D. S., Cash J. D. The release of human platelet specific protein measured by a radioimmunoassay. Thromb. Res. 1975; 6: 543
   PubMed Web of Science ®Google Scholar
• Bolton A. E., Ludlam C. A., Moore S., Pepper D. S., Cash J. D. Three approaches to the radioimmunoassay of human β-thromboglobulin. Br. J. Haematol 1976; 33: 233
   Google Scholar
• Ludlam C. A. β-thromboglobulin test. Lancet June 18, 1977; 1311
   Google Scholar
• Kaplan K. L., Nosse H. L., Drillings M., Lesznik G. Radioimmunoassay of platelet factor 4 and β-thromboglobulin: development and application to studies of platelet release in relation to fibrinopeptide A generation. Br. J. Haematol. 1978; 39: 129
   PubMed Web of Science ®Google Scholar
• Woo J., Pace P., Olson J., Ward R., Cannon D. Evaluation of a radioimmunoassay for beta thromboglobulin and its use in various clinical states. Am. J. Clin. Pathol. 1980; 73: 300
   Google Scholar
• Chesterman C. N., McGready J. R., Doyle D. J., Morgan E. J. Plasma levels of platelet factor 4 measured by radioimmunoassay. Br. J. Haematol. 1978; 40: 489
   Google Scholar
• Bolton A. E., Ludlam C. A., Pepper D. S., Cash J. D. A radioimmunoassay for platelet factor 4. Thromb. Res. 1976; 8: 51
   PubMed Web of Science ®Google Scholar
• Ludlam C. A., Cash J. D. Studies on the liberation of β-thromboglobulin from human platelet in vitro. Br. J. Haematol 1976; 33: 239
   PubMed Web of Science ®Google Scholar
• Dawes J., Smith R. C., Pepper D. S. The release, distribution, and clearance of human β-thromboglobulin and platelet factor 4. Thromb. Res. 1978; 12(5)851
   PubMed Web of Science ®Google Scholar
• Ludlam C. A., Bolton A. E., Moore S., Cash J. D. New rapid method for diagnosis of deep venous thrombosis. Lancet Aug. 9, 1975; 259
   Google Scholar
• Smith R. C., Duncanson J., Ruckley C. V., Webber R. C., Allan N. C., Dawes J., Bolton A. E., Hunter W. M., Pepper D. S., Cash J. D. β-thromboglobulin and deep vein thrombosis. Thromb. Haemost. (Stuttgart) 1978; 39: 338
   PubMed Web of Science ®Google Scholar
• Aranda M., Saez M., Abril V., Cararach J., Castellis E., Castellanos J. M. β-thromboglobulin levels and oral contraception. Lancet Aug. 11, 1979; 308
   Google Scholar
• Schernthaner G., Muhlhauser I., Silberbauer K. β-Thromboglobulin lowered by dipyridamole in diabetes. Lancet Oct. 6, 1979; 748
   Google Scholar
• Duncan A. β-Thromboglobulin levels and oral contraception. Lancet 1979; 631
   Google Scholar
• Matthews J. H., O'Connor F. J., Hearnshaw J. R., Wood J. K. Beta thromboglobulin and glycosylated haemoglobin in diabetes mellitus. Scand. J. Haematol. 1979; 23: 421
   Google Scholar
• Editorial. Platelets, Beta-thromboglobulin, and diabetes mellitus. Lancet Feb. 4, 1978; 250
   Google Scholar
• Burrows A. W., Hockaday T. D. R., Chavin S. I. Plasma-thromboglobulin concentrations in diabetes mellitus. Lancet Feb. 4, 1978; 235
   Google Scholar
• Preston F. E., Marcola B. H., Timperley W. R., Ward J. D., Porter N. R. Elevated β-thromboglobulin levels and circulating platelet aggregates in diabetic microangiopathy. Lancet Feb. 4, 1978; 238
   Google Scholar
• Kaplan K. Proteins secreted by platelets: significance on detecting thrombosis. Adv. Exp. Med. Biol 1978; 102: 105
   PubMedGoogle Scholar
• Redman C. W. G., Allington M. J., Bolton F. G., Stirrat G. M. Plasma β-thromboglobulin in pre-eclampsia. Lancet. July 30, 1977; 248
   Google Scholar
• O'Brien J. R., Etherington M. D., Shuttleworth R. β-thromboglobulin and heparin-neutraliz-ing activity test in clinical conditions. Lancet May 28, 1977; 1153
   Google Scholar
• Ludlam C. A., Anderton J. L. Platelet β-thromboglobulin. Platelet Function Testing, H. J. Day, H. Holmen, M. B. Zucker. Publ. No. 78–1087, National Institutes of Health, U.S. Department of Health, Education, and Welfare. 1978; 267–290
   Google Scholar
• Han P., Turpie A. G. G., Genton E. Plasma β-thromboglobulin: differentiation between intravascular and extravascular platelet destruction. Blood 1979; 54(5)1192
   Google Scholar
• Doyle D. J., Chesterman C. N., Cade J. F., McGready J. R., Rennie G. C., Morgan F. J. Plasma concentrations of platelet-specific proteins correlated with platelet survival. Blood 1980; 55(1)82
   Google Scholar
• Fabris F., Casonato A., Randi M. L., Girolami A. Plasma and platelet beta thromboglobulin levels in patients with May-Hegglin anomaly. Haemostasis 1980; 9: 126
   Google Scholar
• Pariti F. I., Dawes J., Franchi F., Mannucci P. M., Pepper D. S. Content and release of betathromboglobulin and platelet factor 4 in patients with qualitative platelet defects. Thromb. Res. 1979; 16: 537
   Google Scholar
• Schernthaner G., Ludwig H., Silberbauer K. Elevated plasma β-thromboglobulin levels in multiple myeloma and in polycythaemia vera. Acta Haematol 1979; 62: 219
   Google Scholar
• Boughton B. J., Allington M. J., King A. Platelet and plasma β-thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis. Br. J. Haematol 1978; 40: 125
   PubMed Web of Science ®Google Scholar
• Amersham Procedure Booklet: B-thromboglobulin RIA Kit. 1977; 99, Code IM
   Google Scholar
• Ludlam C. A. Evidence for the platelet specificity of β-thromboglobulin and studies on its plasma concentration in healthy individuals. Br. J. Haematol 1979; 41: 271
   PubMed Web of Science ®Google Scholar
• Zahavi J., Cella G., Dubiel M., Kakkar V. V. The variability of plasma β-thromboglobulin in healthy individuals. Thromb. Haemost. (Stuttgart) 1978; 40: 565
   Google Scholar
• Gjesdal K. Platelet factor 4 (PF-4): an electroimmuno assay for PF-4 in human plasma. Scand. J. Haematol 1974; 13: 232
   PubMedGoogle Scholar
• Rucinski B., Niewiarowski S., James P., Walz D. A., Budzynski A. Z. Antiheparin proteins secreted by human platelets. Purification, characterization, and radioimmunoassay. Blood 1979; 53(1)47
   Google Scholar
• Farbiszewski R., Niewiarowski S., Worowski K., Lipinski B. Release of platelet factor 4 in vivo during intravascular coagulation and in thrombotic states. Thromb. Diaih. Haemorrh. 1968; 119: 578
   Google Scholar
• Dana B., Ellman L., Carvalho A., Daggett W. M., Hutter A. M. Plasma heparin neutralizing activity in coronary artery disease. Am. J. Cardiol 1976; 38: 9
   Google Scholar
• Handin R. I., McDonough M., Lesch M. Elevation of platelet factor four in acute myocardial infarction: measurement by radioimmunoassay. J. Lab. Clin. Med. 1978; 91: 341
   Google Scholar
• Fuster V., Kazmier F. J., Cash J. D., Bowie E. J. W., Owen C. A. Assay of platelet factor 4 in plasma. Mayo Clin. Proc 1973; 48: 103
   Google Scholar
• Workman E. F., Clark D. M., Fedor E. J. Platelet factor 4 levels in cardiovascular disorders. Clin. Chem. 1979; 25(6)1147
   Google Scholar
• Green L. H., Seroppian E., Handin R. I. Platelet activation during exercise-induced myocardial ischemia. N. Engl. J. Med. 1980; 302: 193
   PubMed Web of Science ®Google Scholar
• Nossel H. L., Ti M., Kaplan K. L., et al. The generation of fibrinopeptide A in clinical blood samples: the evidence for thrombin activity. J. Clin. Invest. 1976; 58: 136
   Google Scholar
• Nossel H. L. Radioimmunoassay of fibrinopeptides in relation to intravascular coagulation and thrombosis. N. Engl. J. Med. 1976; 295(8)428
   Google Scholar
• Bilezikan S. B., Nossel H. L., Butler V. P., Jr., et al. Radioimmunoassay of human fibrinopeptide B and kinetics of fibrinopeptide cleavage by different enzymes. J. Clin. Invest. 1975; 56: 438
   Google Scholar
• Gollwitzer R., Hafter R., Timpl R., Graeff H. Immunological assay for a carboxyterminal peptide of the fibrinogen A α-chain in a pathological human sera. Thromb. Res. 1977; 11: 859
   Google Scholar
• Yudelman I. M., Nossel H. L., Kaplan K. L., Hirsch J. Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. Blood 1978; 51(6)1189
   Google Scholar
• Wilner G. D., Chatpar P., Te A., Horowitz J. Effects of extravascular clotting on fibrinopeptide A levels in blood. J. Lab. Clin. Med. 1978; 91: 205
   Google Scholar
• Nossel H. L., Ti M., Kaplan K. L., Spanondis K., Soland T., Butler V. P. The generation of fibrinopeptide A in clinical blood samples. J. Clin. Invest. 1976; 58: 1136
   PubMed Web of Science ®Google Scholar
• Nossel H. L., Yudelman I., Canfield R. E., et al. Measurement of fibrinopeptide A in human blood. J. Clin. Invest. 1974; 54: 4353
   Google Scholar
• Wilner G. D. Molecular basis for measurement of circulating fibrinogen derivatives. Progress in Hemostasis and Thrombosis, T. H. Spaet. Grune & Stratton, New York 1978; Vol. 4
   Google Scholar
• Collen D., DeCock F., Verstratte M. Quantitation of thrombin-antithrombin III complexes in human blood. Eur. J. Clin. Invest. 1977; 7: 407
   Google Scholar
• Collen D., DeCock F. Thrombin-antithrombin III and plasmin-antiplasmin complexes as indicators of in vivo activation of the coagulation and/or fibrinolytic systems. Thromb. Haemost. (Stuttgart) 1977; 38: 173
   Web of Science ®Google Scholar
• Workman E. F. A radioimmunoassay for the quantitation of thrombin-antithrombin III complex (TAT) in plasma. Symp. on Contrib. to Hemost. May, 1980. Wayne State University, Detroit
   Google Scholar
• Collen D., DeCock F. A tanned red cell haemagglutination inhibition immunoassay (TRCHII) for the quantitative estimation of thrombin-antithrombin III and plasmin-alpha2 antiplasmin complexes in human plasma. Thromb. Res. 1975; 7: 235
   Google Scholar
• Budzynski A. Z., Marder V. J., Parker M. E., et al. Distinctive neoantigenic marker associated with a plasmic derivitive (fragment D-D) of cross-linked human fibrin. Thromb. Haemost. (Stuttgart) 1977; 38: 192
   Google Scholar
• Budzinski A. Z., Marder V. J., Parker M. E., Shames P., Brizuela B. S., Olexa S. A. Antigen markers on fragment DD, a unique plasmic derivative of human cross-linked fibrin. Blood 1979; 54: 794
   Google Scholar
• Chen J. P., Schulof R. S. Radioimmunoassay of fibrinogen fibrin degradation products: assay for fragment E-related neoantigen-methodological aspects. Thromb. Res. 1979; 16: 601
   Google Scholar
• Plow E., Edgington T. S. Immunobiology of fibrinogen: emergence of neoantigenic expressions during physiologic cleavage in vitro and in vivo. J. Clin. Invest. 1973; 52: 273
   PubMedGoogle Scholar
• Lau H. K., Rosenberg J. S., Beeler D. L., Rosenberg R. D. The isolation and characterization of a specific antibody population directed against the prothrombin activation fragments F2 and F1 + 2. J. Biol Chem. 1979; 254: 8751
   Google Scholar
• McDuffie F. C., Griffin C., Niedringhaus R., Mann K. G., et al. Prothrombin, thrombin and prothrombin fragments in plasma of normal individuals and of patients with laboratory evidence of disseminated intravascular coagulation. Thromb. Res. 1979; 16: 759
   Google Scholar
• Rosenberg R. D., Lau H. K. F., Beeier D., Rosenberg J. S. Assays for hypercoagulability. The thrombotic process in atherogenesis. Adv. Exp. Med. Biol. 1978; 104: 449
   Google Scholar
• Shuman M. A., Majerus P. W. The measurement of thrombin in clotting blood by radioimmunoassay. J. Clin. Inv. 1976; 58: 1249
   PubMed Web of Science ®Google Scholar
• Berkowitz R., Nemerson Y. Quantitation of contact system activation using a radiometric assay for activated factor IX. Blood 1980; 55: 528
   Google Scholar
• MacFarlane R. G. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier. Nature (London) 1964; 202: 498
   PubMed Web of Science ®Google Scholar
• Davie E. W., Ratnoff O. D. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 310
   Google Scholar
• Rosenberg R. D., Damus P. S. The purification and mechanism of action of human anti-thrombin-heparin cofactor. J. Biol. Chem. 1973; 248: 6490
   PubMed Web of Science ®Google Scholar
• Seghatchian M. J., Miller-Andersson M. A colorimetric evaluation of factor VIII: C potency. Med. Lab. Set. 1978; 35: 347
   Google Scholar
• Friberger P., Knos M., Gustavsson S., Aurell L., Claeson G. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 1978; 7: 138
   PubMedGoogle Scholar
• Nieuwenhuizen W., Wijngaards G., Groeneveld E. Fluorogenic substrates for sensitive and differential estimation of urokinase and tissue plasminogen activator. Haemostasis 1978; 7: 146
   PubMedGoogle Scholar
• Fässler H., Walter Mn., Marbet G., Duckert F. The quantitative determination of urokinase with chromozym UK. New Methods for the Analysis of Coagulation Using Chromogenic Substrates, I. Witt. de Gruyter, New York 1977; 249
   Google Scholar
• Gyzander E., Friberger P., Myrwold H., Noppa H., Olsson R., Teger-Nilsson A.-C., Wallmo L. Antiplasmin determination by means of the plasmin specific substrate S-2251 - methodological studies and some clinical applications. New Methods for the Analysis of Coagulation Using Synthetic Chromogenic Substrates, I. Witt. de Gruyter, New York 1977; 229
   Google Scholar
• Lawson D. E., Mitchell G. A., Hnseby R. M. A sensitive fluorescent assay for determining α2-plasmin inhibitor using a synthetic substrate. Thromb. Res. 1979; 14: 323
   PubMed Web of Science ®Google Scholar
• Naito K., Aoki N. Assay of α2-plasmin inhibitor activity by means of a plasmin specific tripeptide substrate. Thromb. Res. 1978; 12: 1147
   PubMedGoogle Scholar
• Teger-Nilsson A.-C., Gyzander E., Myrwold H., Noppa H., Olsson R., Wallmo L. Determination of fast-acting plasmin inhibitor (α2-antiplasmin) in plasma from patients with tendency to thrombosis and increased fibrinolysis. Haemostasis 1978; 7: 155
   PubMedGoogle Scholar
• Blombäck M., Blombäck B., Olsson P., Svendson L. The assay of antithrombin using a synthetic cromogenic substrate for thrombin. Thromb. Res. 1974; 5: 621
   PubMed Web of Science ®Google Scholar
• Blow D. M., Birktoft J. J., Hartley B. S. Role of a barried acid group in the mechanism of action of chymotrypsin. Nature (London) 1969; 221: 337
   PubMed Web of Science ®Google Scholar
• Schwert G. W., Neurath H., Kaufman S., Snoke J. K. The specific esterase activity of trypsin. J. Biol. Chem. 1948; 172: 221
   PubMed Web of Science ®Google Scholar
• Troll W., Sherry S., Wachman J. The action of thrombin on synthetic substrates. J. Biol. Chem. 1954; 208: 85
   PubMed Web of Science ®Google Scholar
• Sherry S., Troll W. The action of plasmin on synthetic substrates. J. Biol. Chem. 1954; 208: 95
   PubMed Web of Science ®Google Scholar
• Werle E., Kaufmann-Boetsch B. Ueber eine esterspaltende Wirkung von Kallikrein. Natur-wissenschaften 1959; 46: 559
   Google Scholar
• Habermann E. Ueber Zusammanhänge zwischen esterolytischen und pharmakologischen Wirkungen von Jararacagift, Kallikrein und Thrombin Nauyn-Schmiedebergs. Arch. Exp. Pathol. Pharmacol. 1959; 236: 492
   PubMedGoogle Scholar
• Erlanger B. F., Kokowski N., Cohen W. The preparation and properties of two new chromogenic substrates of trypsin. Arch. Biochem. Biophys. 1961; 95: 271
   PubMed Web of Science ®Google Scholar
• Blombäck B., Blombäck M., Hessel B., Iwanaga S. Structure of N-terminal fragments of fibrinogen and specificity of thrombin. Nature (London) 1967; 215: 1445
   Google Scholar
• Blombäck B., Hessel B., Iwanaga S., Reuterby J., Blombäck M. Primary structure of fibrinogen and fibrin. I. Cleavage of fibrinogen with cyanogen bromide. Isolation and characterization of NH2-terminal fragments of the a (“A”) chain. J. Biol. Chem. 1972; 247: 1496
   Google Scholar
• Blombäck B. Fibrinogen and synthetic substrate specificity. Chemistry and Biology of Thrombin, R. L. Lundblad, J. W. Fenton, II, J. W. Mann. Ann Arbor Science, Michigan 1977; 275
   Google Scholar
• Svendsen L., Blombäck B., Blombäck M., Olsson P. Synthetic chromogenic substrates for determination of trypsin, thrombin and thrombin-like enzymes. Thromb. Res. 1972; I: 267
   Google Scholar
• Svendsen L., Blombäck B., Blombäck M., Olsson P. I. Substrates for determination of trypsin, thrombin and thrombin-like enzymes. Folia Haematol. 1972; 98: 446
   Google Scholar
• Morita T., Kato H., Iwanaga S., Takada K., Kimura T., Sakakibara S. New fluorogenic substrates for α-thrombin, factor Xa, kallikreins, and urokinase. J. Biochem. 1977; 82: 1495
   PubMed Web of Science ®Google Scholar
• Iwanaga S., Kato H., Maruyana I., Adadie N., Ohno Y., Takada K., Kimura T., Sakakibara S. Fluorogenic peptide substrates for proteases in blood coagulation. Kallikrein-kinin and Fibrinolysis system: substrate for plasmin and factor XA. Thromb. Haemost. (Stuttgart) 1979; 42: 49
   Google Scholar
• Korsan-Bengtsen K., Axelsson G., Waldenstrom J. Determination of plasma prothrombin with the chromogenic peptide substrate H-D-Phe-Pip-Arg-pNA (S-2238). New Methods for the Analysis of Coagulation Using Chromogenic Substrates, I. Witt. de Gruyter, New York 1977; 145
   Google Scholar
• Witt I. Determination of plasma prothrombin with chromozym TH. New Methods for the Analysis of Coagulation Using Chromogenic Substrates, I. Witt. de Gruyter, New York 1977; 155
   Google Scholar
• Svendson L. The use of chromogenic substrates at present and in the future for factors of the coagulation fibrinolytic and kallikrein-kinin systems. Chromogenic Peptide Substrates Chemistry and Clinical Usage, M. F. Scully, V. V. Kakkar. Churchill Livingstone, London 1979; 13
   Google Scholar
• Mitchell G. A., Hudson P. M., Huseby R. M., Pochran S. P., Gargiulo R. J. Fluorescent substrate assay for antithrombin III. Thromb. Res. 1978; 12: 219
   PubMed Web of Science ®Google Scholar
• Claeson G., Aurell L., Karlsson G., Gustavsson S., Friberger P., Arielly S., Simonsson R. Design of chromogenic peptide substrates. Chromogenic Peptide Substrates, Chemistry and Clinical Usage. Churchill Livingstone, London 1979; 20
   Google Scholar
• Abildgaard U., Lie M., Odegard O. R. Antithrombin (heparin cofactor) assay with 'new' chromogenic substrates (S-2238 and chromozym-TH). Thromb. Res. 1977; 11: 549
   PubMed Web of Science ®Google Scholar
• Axelsson G., Korsan-Bengtsen K., Waldenstrom J. Prothrombin determination by means of a chromogenic peptide substrate. Thromb. Haemost. (Stuttgart) 1976; 36: 517
   Google Scholar
• Larsen M. L., Abildgaard U., Teien A. N., Gjesdal K. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). Thromb. Res. 1978; 13: 285
   Google Scholar
• Vinazzer H., Heimburger N. Assay of factor Xa in intact plasma as a possible method for early diagnosis of intravascular coagulation. Thromb. Res. 1978; 12: 503
   Google Scholar
• Aurell L., Friberger P., Karlsson G., Claeson G. A new sensitive and highly specific chromogenic peptide substrate for factor Xa. Thromb. Res. 1977; 11: 595
   PubMed Web of Science ®Google Scholar
• Teien A. N., Lie M., Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb. Res. 1976; 8: 413
   PubMed Web of Science ®Google Scholar
• Odegard O. R., Lie M., Abildgaard U. Antifactor Xa activity measured with amidolytic methods. Haemostasis 1976; 5: 265
   Google Scholar
• Vinazzer H. Photometric assay of platelet factor 4 with a chromogenic substrate. Haemostasis 1977; 6: 283
   Google Scholar
• Kwaan H. C., Friedman R. B., Szczecinski J. Amplification of color yield of chromogenic substrates using p-dimethylaminocinnamaldehyde. Thromb. Res. 1978; 13: 5
   Google Scholar
• Bergström K., Blombäck M. Determination of plasma prothrombin with a reaction rate analyzer using a synthetic substrate. Thromb. Res. 1974; 4: 719
   PubMed Web of Science ®Google Scholar
• Odegard O. R., Rosenlund B., Ervick E. Automated antithrombin III assay with a centrifugal analyzer. Haemostasis 1978; 7: 202
   Google Scholar
• Dunikoski L. K. Automated chromogenic antithrombin III assay with a centrifugal analyzer. Clin. Chem. 1979; 25: 1076
   Google Scholar
• Francis J. L. A new chromogenic assay for the specific determination of prothrombin 1979; 32: 651
   Google Scholar
• Andreasen T. Automated two-stage assay for determination of antithrombin III with a centrifugal analyzer. Haemostasis 1980; 9: 65
   Google Scholar
• Bertina R. M., Vander Marel-Van N., Loeliger E. A. Spectrophotometric assay of prothrombin in plasma of patients using oral anticoagulants. Thromb. Haemost. (Stuttgart) 1980; 42: 1296
   Google Scholar
• Mibashan R. S., Scully M. F., Birch A. J., Thumpston J. K., Macgregor I. R., Kakkar V. V. Automated control of coumarin therapy by chromogenic factor X assay. Thromb. Haemost. (Stuttgart) 1979; 42: 291
   Google Scholar
• Gray A. J., Uhlmeyer K. A., Fedor E. J. Quantichrom AT III diagnostic kit for the quantification of total AT III in plasma. Thromb. Haemost. (Stuttgart) 1979; 42: 225
   Google Scholar
• Mitchell G. A., Gargiulo R. J., Huseby R. M. Assay for plasma heparin using a synthetic peptide substrate for thrombin. Thromb. Res. 1978; 13: 47
   PubMed Web of Science ®Google Scholar
• Pochran S. P., Mitchell G. A., Albareda I., Huseby R. M., Gargiulo R. J. A fluorescent substrate assay for plasminogen. Thromb. Res. 1978; 13: 733
   Google Scholar
• Stormorken H. Advantages and disadvantages of assaying coagulation and fibrinolytic parameters using chromogenic substrates. Chromogenic Peptide Substrates—Chemistry and Clinical Usage, M. F. Scully, V. V. Kakkar. Churchill Livingstone, London 1979; 32
   Google Scholar
• Johnson A. J., Kline D. L., Alkjaersig N. Assay methods and standard preparations for plasmin, plasminogen and urokinase in purified systems, 1967–1968. Thromb. Diath. Haemorrh. (Stuttgart) 1969; 21: 259
   PubMedGoogle Scholar
• Odegard O. R., Lie M., Abildgaard U. Heparin cofactor activity measured with an amidolytic method. Thromb. Res. 1975; 6: 287
   PubMed Web of Science ®Google Scholar
• Abildgaard U., Lie M., Odegard O. R. A simple amidolytic method for the determination of functionally active antithrombin III. Scand. J. Clin. Lab. Invest. 1976; 36: 109
   PubMedGoogle Scholar
• Odegard O. R. Evaluation of an amidolytic heparin cofactor assay method. Thromb. Res. 1975; 7: 351
   PubMed Web of Science ®Google Scholar
• Miller-Andersson M., Seghatchian J. Microheterogeneity in thrombin standards. Haemostasis 1978; 7: 113
   Google Scholar
• Gaffney P. J., Lord K., Brasher M., Kirkwood T. B. L. Problems in the assay of thrombin using synthetic peptides as substrates. Thromb. Res. 1977; 10: 549
   Google Scholar
• Gaffney P. J. A critical evaluation of chromogenic substrates in standardization. Chromogenic Peptide Substrates Chemistry and Clinical Usage, M. F. Scully, V. V. Kakkar. Churchill Livingstone, London 1979; 42
   Google Scholar
• Latallo Z. S., Teisseyre E. Amidolytic assay of prothrombin activated with ecarin, a pro-coagulant from Echis carinatus venom. New Methods for the Analysis of Coagulation Using Chromogenic Substrates, I. Witt. de Gruyter, New York 1977; 181
   Google Scholar
• Triplett D. A., Harms C., Huseby R. M., Mitchell G. A., Pochron S. P. Clinical studies of the use of a fluorogenic substrate assay for the determination of antithrombin III activity. Abstracts. VIIth International Congress on Thrombosis and Haemostasis. Thromb. Haemost. (Stuttgart) 1979; 42: 20
   Google Scholar
• Triplett D. A., Harms C., Huseby R. M., Mitchell G. A., Pochron S. P. The use of the fluorogenic synthetic substrate assay for the clinical determination of heparin. Abstracts. VIIth International Congress on Thrombosis and Haemostasis. Thromb. Haemost. (Stuttgart) 1979; 42: 308
   Google Scholar
• Triplett D. A., Harms C., Hermelin L., Huseby R. M., Mitchell G. A., Pochron S. P. Clinical studies of the use of a fluorogenic substrate assay method for the determination of plasminogen. Abstracts. VIIth International Congress on Thrombosis and Haemostasis. Thromb. Haemost. (Stuttgart) 1979; 42: 50
   Google Scholar
• Holm H. A., Abildgaard U., Bjerkelund C. Heparin treatment of deep venous thrombosis: clinical usefulness of blood tests. Abstracts. VIIth International Congress on Thrombosis and Haemostasis. Thromb. Haemost. (Stuttgart) 1979; 42: 306
   Google Scholar
• Mattler L. E., Bang N. V. Serine protease specificity for peptide chromogenic substrates. Thromb. Haemostas. (Stuttgart) 1977; 38: 776
   PubMedGoogle Scholar
• Triplett D. A., Harms C. S. The use of synthetic substrates in the diagnostic clinical laboratory. Perspectives in Hemostatis, J. Fareed, J. W. Femton. Pergamon Press, New York 1981
   Google Scholar
• Jolgren U. R., Triplett D. A. Immunologic methods in the coagulation laboratory. Thrombosis and hemostasis check sample TH80–4 (TH-10). American Society of Clinical Pathologists, Chicago 1980
   Google Scholar